Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 11Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Carcinoma, Renal Cell 4Leukemia, Myeloid, Chronic-Phase 3Kidney Neoplasms 3Neoplasm Metastasis 2Lymphoma 2Leukemia 2Hepatitis B, Chronic 2Carcinoma, Hepatocellular 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Sezary Syndrome 1Recurrence 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Ovarian Neoplasms 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Mycosis Fungoides 1Meningeal Carcinomatosis 1

Interventions

Cisplatin 55Radiotherapy 33Cetuximab 25Paclitaxel 23Carboplatin 23Radiotherapy, Intensity-Modulated 21pembrolizumab 19Docetaxel 17Fluorouracil 16Nivolumab 14Drug Therapy 11Radiation 9Erlotinib Hydrochloride 8Blood Specimen Collection 8durvalumab 7Magnetic Resonance Spectroscopy 7Surveys and Questionnaires 6atezolizumab 5Surgical Procedures, Operative 5Radiosurgery 5Esophagectomy 5Chemoradiotherapy 5olaparib 4dacomitinib 4Leucovorin 4Cyclophosphamide 4Capecitabine 4Biopsy 4Afatinib 4fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Squamous Cell × peginterferon alfa-2b × Clear all
NCT02218164 2022-10-07

Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
8 enrolled 11 charts
Dermatologic

Carcinoma, Squamous Cell, Neoplasm Metastasis, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡